Highest-materiality recent filing
Seres Therapeutics board member Hans-Juergen Woerle resigns, effective May 31, 2026
Dr. Woerle resigned from the board and all committees, effective May 31, 2026.
Seres Q1 2026 net loss $19.9M; cash runway only through Q3 2026
Net loss $19.9M vs net income $32.7M in Q1 2025 (which included $50M Nestlé payment).
Seres Therapeutics sets 2026 annual meeting for June 9
Record date for voting is April 13, 2026; stockholders of record on that date are entitled to vote.
Full-year 2025 net income from continuing ops $5.7M vs net loss of $125.8M in 2024; Q4 net loss $15.3M.
Seres Therapeutics appoints Richard Kender as Interim CEO, effective March 2
Thomas DesRosier and Marella Thorell step down as co-Presidents/co-CEOs but remain EVP CLO and EVP CFO.
Net income from continuing ops $8.2M vs loss of $51.0M in Q3 2024, driven by $27.2M gain on VOWST sale.
Seres Therapeutics cuts workforce 25%, extends cash runway into Q2 2026
Reducing workforce by approximately 25%, including reductions effective August 2025.
Seres Q2 net loss narrows to $19.9M; CEO replaced; SER-155 Phase 2 protocol filed
Net loss from continuing ops $19.9M in Q2 2025 vs $26.2M in Q2 2024; cash $45.4M as of June 30.
Seres Therapeutics CEO Eric Shaff resigns; CFO and CLO appointed as Co-CEOs effective Aug 1, 2025
Eric Shaff resigns as President and CEO effective July 31, 2025; remains on Board as Class I director.
Seres Q1 net income $32.7M; SER-155 Phase 2 protocol to FDA in weeks
Net income from continuing ops of $32.7M vs net loss of $32.9M YoY, driven by $50M Nestlé installment.
Seres Therapeutics effects 1-for-20 reverse stock split, effective April 21, 2025
Reverse stock split at 1-for-20 ratio, effective 5:00 PM ET on April 21, 2025.
Seres Therapeutics stockholders approve 1-for-20 reverse stock split, 2025 Incentive Plan
Reverse stock split at 1-for-20 ratio approved; effective April 21, 2025; trading on split-adjusted basis April 22 under symbol MCRB.
Seres Q4 net loss from continuing ops $15.7M; cash extends into Q1 2026; SER-155 advances
Net loss from continuing ops: FY2024 $125.8M vs $190.1M in 2023; Q4 $15.7M vs $34.7M.
Seres Therapeutics CMO Lisa von Moltke resigns effective March 14, 2025
Lisa von Moltke, M.D., notified Seres of her resignation as EVP and Chief Medical Officer.
Seres Therapeutics appoints Hans-Juergen Woerle, M.D. to board, designated by Nestlé
Board expanded to nine directors; Woerle appointed as Class III director effective Feb 4, 2025.
Company posted updated corporate presentation on investor website ahead of J.P. Morgan Conference on January 16, 2025.
Seres reports $31M cash, SER-155 biomarker data positive, FDA Breakthrough Therapy
Prelim cash $31M as of Dec 31, 2024; with Nestlé payments of ~$75M, cash runway into Q1 2026.
Nasdaq notified Seres (MCRB) that bid price closed below $1.00 for 30 consecutive business days; must regain compliance by May 6, 2025.
Seres completes VOWST sale to Nestlé for ~$175M gross; debt retired, runway to Q4 2025
Received ~$175M gross at close: $100M upfront, $60M prepaid milestone, $15M equity; net ~$155M after ~$20M settlement.
Seres stockholders approve sale of VOWST business to Nestlé; close expected Sept 30
Stockholders voted 77.1M for, 7.1M against, and 0.2M abstain to approve the sale of VOWST business to Société des Produits Nestlé S.A.
Seres' SER-155 reduces BSIs 10% vs 42.9% in allo-HSCT Phase 1b; seeks Breakthrough Therapy
SER-155 cut bloodstream infections to 10% vs 42.9% placebo (p=0.0423) in 34 evaluable patients.
Seres files prior financials for proxy on VOWST asset sale; auditor flags going concern
Furnishes 2022-2023 audited financial statements for incorporation in proxy statement related to sale of VOWST microbiome assets.
Seres Q2 net loss $32.9M; VOWST sales $14.4M (+43% QoQ); announces $175M asset sale to Nestlé
Net loss $32.9M vs net income $46.6M in Q2 2023 (prior year included $125M VOWST milestone from Nestlé).
Seres sells VOWST to Nestlé Health Science for $175M upfront plus milestones
Seres to receive $175M at closing: $100M upfront (less ~$20M net settlement), $60M prepaid milestone, $15M equity at $1.05/share.
Seres sells VOWST business to Nestlé for up to $100M cash plus milestones; issues $15M stock
Cash payment of $100M at closing (net of ~$17.9M owed to Nestlé affiliate and ~CHF2M to Bacthera); $50M due Jan 2025, $25M July 2025.
On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc. (the “Company”) and on the committees on which he serves, effective May 31, 2026.
On February 22, 2025, Lisa von Moltke, M.D. notified Seres Therapeutics, Inc. (the “Company”) of her intention to resign as the Executive Vice President and Chief Medical Officer of the Company, effective as of March 14, 2025.
appointed Hans-Juergen Woerle, M.D., as a Class III director of the Company, effective immediately.
Max materiality 0.95 · Median 0.70 · Most common event other_material